LIFECARE

PRESS RELEASE
11 March 2026 15:29:00 CET

CORRECTION: LIFECARE ASA: MANDATORY NOTIFICATION OF TRADE

Teigland Eiendom AS has exercised 4,787,552 Warrants for the subscription of 4,787,552 new shares in the Company.

Reference is made to the stock exchange announcement by Lifecare ASA (the "Company") on 2 March 2026 regarding the commencement of the exercise period for Warrants Series 1 issued in connection with the partially underwritten rights issue completed in January 2026.

Each Warrant Series 1 entitles the holder to subscribe for one new share in the Company at an exercise price of NOK 0.3342 per share.

The exercise period for Warrants Series 1 commenced on 2 March 2026 and expires at 16:30 (CET) on 13 March 2026 (the "Exercise Period"). Warrants that are not exercised to subscribe for new shares before the end of the Exercise Period will have no value and will lapse without compensation to the holder. Holders of Warrants who do not exercise their Warrants within the Exercise Period may experience dilution of their shareholding in the Company.

The Company has been informed that Teigland Eiendom AS, a company closely associated with Trine Teigland, board member and primary insider of Lifecare ASA, has exercised 4,787,552 Warrants for the subscription of 4,787,552 new shares in the Company at a price of NOK 0.3342 per share.

Following this transaction, Teigland Eiendom AS holds **12,682,136** shares and 3,072,448 warrants in Warrant Series 1 and 7,860,000 warrants in Warrant Series 2 in the Company.

Subject to timely payment of the aggregate subscription amount for the new shares issued upon exercise of Warrants Series 1, the Company expects that the share capital increase will be registered with the Norwegian Register of Business Enterprises on or about 25 March 2026, and that the new shares will be delivered to the VPS accounts of the subscribers on or about 26 March 2026.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-11 15:29 CET.

Attachments

260311 PDMR Attachment Teigland Eiendom